GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » 4Front Ventures Corp (OTCPK:FFNTF) » Definitions » Net-Net Working Capital

4Front Ventures (4Front Ventures) Net-Net Working Capital : $-0.45 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is 4Front Ventures Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

4Front Ventures's Net-Net Working Capital for the quarter that ended in Dec. 2023 was $-0.45.

The industry rank for 4Front Ventures's Net-Net Working Capital or its related term are showing as below:

FFNTF's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.78
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

4Front Ventures Net-Net Working Capital Historical Data

The historical data trend for 4Front Ventures's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4Front Ventures Net-Net Working Capital Chart

4Front Ventures Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.33 -0.25 -0.31 -0.45 -0.45

4Front Ventures Quarterly Data
Jan19 Apr19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.45 -0.45 -0.46 -0.46 -0.45

Competitive Comparison of 4Front Ventures's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, 4Front Ventures's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


4Front Ventures's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, 4Front Ventures's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where 4Front Ventures's Price-to-Net-Net-Working-Capital falls into.



4Front Ventures Net-Net Working Capital Calculation

4Front Ventures's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.398+0.75 * 3.682+0.5 * 17.087-315.348
-0-0.108)/669.519
=-0.45

4Front Ventures's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(3.398+0.75 * 3.682+0.5 * 17.087-315.348
-0-0.108)/669.519
=-0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


4Front Ventures  (OTCPK:FFNTF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


4Front Ventures Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of 4Front Ventures's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


4Front Ventures (4Front Ventures) Business Description

Traded in Other Exchanges
Address
5060 North 40th Street, Suite 120, Phoenix, AZ, USA, 85018
4Front Ventures Corp is a Canadian-based company. It is engaged in the cultivation, processing, extracting, manufacturing, and distribution of cannabis products. It operates in two segments: THC Cannabis and CBD Wellness. The THC Cannabis segment engages in the production and cultivation of THC cannabis, manufacturing and distribution of cannabis products to own dispensaries and third-party retail customers. The CBD Wellness segment encompasses the production and sale of CBD products to third-party customers.
Executives
Leonid Gontmakher director, officer: Chief Executive Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Nicole Frederick officer: See Remarks C/O 4FRONT VENTURES CORP., 7010 E. CHAUNCEY LANE STE. 235, PHOENIX AZ 85054
Kristopher Krane director 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
David Ryan Daily director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Roman Tkachenko director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Karl Chowscano other: Consultant 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Chetan Gulati director 28 REICHERT CIRCLE, WESTPORT CT 06880
Keith Edward Adams officer: Chief Financial Officer 108 S. WETHERLY DRIVE, UNIT 4, LOS ANGELES CA 90048
Robert E Hunt director C/O GROWLIFE, INC., 20301 VENTURA BLVD., SUITE 126, WOODLAND HILLS CA 91364
Amit Ramanlal Patel director 3305 PINE AVENUE, MANHATTAN BEACH CA 90266
Kathi P Lentzsch director 5060 N 40TH STREET STE 120, PHOENIX AZ 85018
Andrew Thut officer: Chief Investment Officer 5060 N. 40TH STREET, SUITE 120, PHOENIX AZ 85018
Joseph R Feltham officer: Chief Operating Officer 5060 N. 40TH STREET, STE 120, PHOENIX AZ 85018
Eric J. Rey director ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Nicolle Dorsey officer: Chief Financial Officer C/O REAL GOODS SOLAR, INC., 110 16TH STREET, 3RD FLOOR, DENVER CO 80202